The ICRN is a global collaboration of research groups from renowned institutions who are working in concert to improve knowledge about cholangiocarcinoma etiology, prevention, early detection, treatment, and prognosis. The network is comprised of highly talented individuals from a spectrum of disciplines, perspectives, and research methods who share a passion to make significant scientific advances to improve outcomes for patients with cholangiocarcinoma.

MISSION

• Improve the prognosis and quality of life for patients with cholangiocarcinoma, and ultimately cure this disease
• Advance the pace of cholangiocarcinoma research
• Provide a platform for investigators to work collaboratively on cholangiocarcinoma-related projects
• Foster promising clinical and translational studies relevant to cholangiocarcinoma
• Catalyze and expand patient access to clinical trials for promising new treatments
• Enable scientists to rapidly share discoveries and accelerate the drug development landscape
• Provide scientifically valid consensus opinions on the diagnosis and treatment of cholangiocarcinoma

ACTIVITIES

• Identifying specific areas of expertise within the ICRN institutions and/or engaging key stakeholders
• Convening participating institutions and/or stakeholders to support the identification, design, and implementation of multi-center clinical research initiatives focused on cholangiocarcinoma
• Attracting and supporting the training of the next generation of cholangiocarcinoma investigators and incentivizing senior researchers to focus in the field
• Identifying critical research gaps and establishing priority areas in cholangiocarcinoma research
• Avoiding unnecessary duplication and reducing regulatory burden involved in network studies
• Enabling ethical research and collaboration between academia and study sponsors
• Consolidating state of the art information and sharing network resources (biobanks, databases, pre-clinical models and repositories)
• Stimulating rapid progress by integrating multiple researcher efforts and strategies
• Facilitating collaborations between industry, regulatory, academia and relevant stakeholders
• Providing peer-review and vetting of clinical trial protocols to expedite development of novel and effective therapies
• Creating online searchable resources for patients looking for innovative research options
• Building molecular databases with clinical annotation to define ‘targetable’ disease subsets

WORKING GROUPS

• Surgical and Transplantation Working Group
  To spearhead efforts in surgical research and liver transplantation for cholangiocarcinoma patients and international surgical trials
• Radio-diagnostic and Radiation Oncology Working Group
  To increase utilization of radiation for treating cholangiocarcinoma patients in Asia and Europe, radiotherapy clinical trials, retrospective studies
• Genomic and Database Research Working Group
  To initiate genomic research projects, RedCap database for clinical research
• Biliary Cancer Alterations Predict Therapy Choice (BATCH) Working Group
  To explore new targeted therapy approaches for various cholangiocarcinoma subtypes across multiple parallel single arm trials
• Immuno-oncology Working Group
  To coordinate immune-oncology trials and study immune biomarker expression in cholangiocarcinoma
• Translational Working Group
  To study and implement translational initiatives
• Biorepository Working Group
  Coordinate the ICRN tissue and blood banking repository
• Members must acknowledge the Cholangiocarcinoma Foundation within publications stemming from ICRN work
• Members agree to share de-identified patient data and cholangiocarcinoma lab resources, including cell lines and PDX models after signing Data and Research Material Ownership, Access and Use Terms (DUAs) with the Cholangiocarcinoma Foundation

MEMBERSHIP BENEFITS

• Convene regularly with a global network of elite cholangiocarcinoma clinicians and researchers
• Access to the Cholangiocarcinoma Foundation International Cholangiocarcinoma Patient Registry (ICPR) database
• Collaborate with other members from worldwide institutions on a multi-center clinical trials and projects facilitated by the Cholangiocarcinoma Foundation
• Develop a cohesive industry strategy through working with CCF’s industry network
• Leadership opportunities by presenting ideas to the ICRN leadership and
• Accessing funding streams facilitated by CCF

MEMBERSHIP ELIGIBILITY

• Membership is free and open to properly credentialed scientists and researchers whose clinical/research interests are focused on cholangiocarcinoma
• Members must sign a Confidentiality Disclosure Agreement (CDA) and agree to participate actively in ICRN meetings and initiatives
ICRN MEMBER INSTITUTIONS

- Acibadem University Atakent Hospital, Turkey
- Banner Health, AZ, CO, WY, NE, NV, CA
- Beth Israel Deaconess Hospital, MA
- Canyon Surgical Associates, UT
- Christie NHS Foundation Trust, UK
- Chulalongkorn University, Thailand
- Cleveland Clinic, OH
- Duke University, NC
- Eastern Hepatobiliary Surgery Hospital, China
- Emory University, Atlanta, GA
- Fred Hutchinson Cancer Research Center, WA
- Hacettepe Cancer Institute, Turkey
- Hannover Medical School, Germany
- Harvard University/MGH, Boston, MA
- Hepatobiliary Medical Society of Western Returned Scholars Association, China
- Huntsman Cancer Institute/University of Utah, UT
- Instanbul Florence Nightingale Hastanesi, Turkey
- Institut Gustav Roussey, Paris
- IRCCS Istituto Nazionale Tumori Milan, Italy
- Johns Hopkins University, Baltimore, MD
- Kaohsiung Medicine University, Taipei, Taiwan
- Mayo Clinic, AZ, FL, MN
- Memorial Sloan Kettering Cancer Center, NY
- MD Anderson Cancer Center, Houston, TX
- Moffitt Cancer Center, FL
- Mount Sinai, NY
- Nancy University, France
- National Cancer Institute Hospital, Japan
- NYU Perlmutter Cancer Center, NY
- Oregon Health & Science University, OR
- Peking Union Medical College Hospital, China
- Pusan National University Hospital, South Korea
- Rhode Island Hospital, Brown University, RI
- Roswell Park Cancer Institute, NY
- Rutgers Cancer Institute of New Jersey, NJ
- Seoul National University College of Medicine, South Korea
- Siriraj Hospital, Thailand
- Stanford University Cancer Center, CA
- Taipei Veterans General Hospital, Taiwan
- The Chinese University of Hong Kong, China
- Trinity College Dublin, Ireland
- Università degli Studi di Verona, Italy
- University College London Hospitals, UK
- University Hospitals Cleveland Medical Center
- University Hospitals of Birmingham, UK
- University of Amsterdam, Netherlands
- University of Arizona Cancer Center, Tucson, AZ
- University of Calgary, Canada
- University of California, San Francisco, CA
- University of California, Norris Comprehensive Cancer Center, CA
- University of Cincinnati, OH
- University of Copenhagen, Denmark
- University of Miami, FL
- University of Michigan, Ann Arbor, MI
- University of New Mexico Comprehensive Cancer Center, NM
- University of Nottingham, UK
- University of Southampton, UK
- University of Southern California, Los Angeles, CA
- University of Tennessee Health Science Center - Baptist Memorial Medical Group
- University of Toronto, Canada
- University of Vermont, VT
- University of Washington, WA
- Vanderbilt University, Nashville, TN
- Virginia Mason Hospital & Medical Center, WA
- Washington University in St. Louis, MO
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, China
- Yale University, CT
- Zhongshan Hospital, China

For more information, please visit: curecc.org/icrn

cholangiocarcinoma.org

01/2020